Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs)
$64.17
neg -0.22
-0.34%
Today's Range: 63.42 - 65.68 | VRTX Avg Daily Volume: 1,671,900
Last Update: 04/17/14 - 4:00 PM EDT
Volume: 1,385,823
YTD Performance: -13.34%
Open: $64.18
Previous Close: $64.39
52 Week Range: $51.96 - $89.96
Oustanding Shares: 235,771,942
Market Cap: 14,934,121,760
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 13 12 12
Moderate Buy 1 1 1 1
Hold 5 5 5 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.65 1.58 1.61 1.68
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -39.90
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-39.90 0.00 28.65
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-20.51% 18.39% 34.09%
GROWTH 12 Mo 3 Yr CAGR
Revenue -20.60 7.45 1.02
Net Income 0.00 -0.09 0.00
EPS 0.00 -0.47 0.00
Earnings for VRTX:
EBITDA -0.15B
Revenue 1.21B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $-0.79 $-0.66 $-2.26 $0.69
Number of Analysts 5 5 9 7
High Estimate $-0.74 $-0.60 $-1.55 $1.86
Low Estimate $-0.88 $-0.75 $-2.55 $-1.16
Prior Year $-0.12 $-0.22 $-1.47 $-2.26
Growth Rate (Year over Year) -556.67% -201.82% -53.67% 130.67%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Robert Moreno

 | Mar 20, 2014 | 2:06 PM EDT

You don't need much conviction to trade these two names.

By

Jim Cramer

 | Jan 30, 2014 | 12:50 PM EST

These types of companies are winners today.

bullishVertex Pharm upgraded at UBS

Jan 6, 2014 | 7:26 AM EST

VRTX was upgraded to Buy from Neutral, UBS said. Driven by confidence that lumicaftor-ivacaftor combination will be successful in 2014 ph3 readouts in cystic fibrosis. $99 price target. 

bearishVertex estimates, target cut at Credit Suisse

Oct 30, 2013 | 7:59 AM EDT

Shares of VRTX now seen reaching $78, according to Credit Suisse. Estimates also reduced, given lower Incivek sales. Neutral rating. 

bullishVertex rated new Outperform at Oppenheimer

Aug 22, 2013 | 7:13 AM EDT

Coverage of VRTX was started with an Outperform rating, Oppenheimer said. $105 price target. Cystic Fibrosis treatments can continue to drive growth. 

 

bullishVertex Pharmaceuticals numbers raised at UBS

Jul 30, 2013 | 8:18 AM EDT

VRTX earnings estimates reflect an increased outlook for Kalydeco, said UBS. Price target is now $84.

By

Doug Kass

 | Jul 29, 2013 | 8:15 AM EDT
Let's start by taking a peek at the overnight and early-morning price action of the major asset classes.

bearishVertex Pharmaceuticals downgraded at UBS

Jul 26, 2013 | 8:07 AM EDT

Shares of VRTX were downgraded to a Neutral rating and given a $83 price target based on the safety concerns for VX-135, UBS said.

By

Gary Dvorchak

 | Jul 19, 2013 | 7:00 AM EDT

Stick with solid investing precepts.

By

James "Rev Shark" DePorre

 | Jul 1, 2013 | 4:05 PM EDT

We are seeing some hot pockets of momentum.

There were nice reversal-type candles on the weekly charts of the major indices. The DOW a...
A number of stocks on my watch lists are attempting to form positive candles a key suppor...
While last week was a day to pull the plug and contemplate where the market was headed, I ...
Shares of TSLA have formed multiple hammer candles at a key level of support defined by: t...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.